Structural and functional features of enzymes of Mycobacterium tuberculosis peptidoglycan biosynthesis as targets for drug development

被引:54
|
作者
Moraes, Gleiciane Leal [1 ]
Gomes, Guelber Cardoso [1 ,2 ]
Monteiro de Sousa, Paulo Robson [1 ]
Alves, Claudio Nahum [1 ]
Govender, Thavendran [3 ]
Kruger, Hendrik G. [3 ]
Maguire, Glenn E. M. [3 ]
Lamichhane, Gyanu [4 ]
Lameira, Jeronimo [1 ,2 ]
机构
[1] Fed Univ Para, Inst Ciencias Exatas & Nat, Lab Planejamento Farmacos, BR-66075110 Belem, Para, Brazil
[2] Fed Univ Para, Inst Ciencias Biol, BR-66075110 Belem, Para, Brazil
[3] Univ KwaZulu Natal, Sch Hlth Sci, Catalysis & Peptide Res Unit, Durban, South Africa
[4] Johns Hopkins Univ, Sch Med, Taskforce Study Resistance Emergence & Antimicrob, Baltimore, MD 21231 USA
关键词
TB; Homology modelling; Peptidoglycan; Drug design; UDP-N-ACETYLGLUCOSAMINE; L-ALANINE LIGASE; ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE MURB; ALANYL-D-GLUTAMATE; ENOLPYRUVYL TRANSFERASE MURA; ANGSTROM CRYSTAL-STRUCTURE; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; ADDING ENZYME; PHOSPHOGLUCOSAMINE MUTASE;
D O I
10.1016/j.tube.2015.01.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Tuberculosis (TB) is the second leading cause of human mortality from infectious diseases worldwide. The WHO reported 1.3 million deaths and 8.6 million new cases of TB in 2012. Mycobacterium tuberculosis (M. tuberculosis), the infectious bacteria that causes TB, is encapsulated by a thick and robust cell wall. The innermost segment of the cell wall is comprised of peptidoglycan, a layer that is required for survival and growth of the pathogen. Enzymes that catalyse biosynthesis of the peptidoglycan are essential and are therefore attractive targets for discovery of novel antibiotics as humans lack similar enzymes making it possible to selectively target bacteria only. In this paper, we have reviewed the structures and functions of enzymes GlmS, GlmM, GlmU, MurA, MurB, MurC, MurD, MurE and MurF from M. tuberculosis that are involved in peptidoglycan biosynthesis. In addition, we report homology modelled 3D structures of those key enzymes from M. tuberculosis of which the structures are still unknown. We demonstrated that natural substrates can be successfully docked into the active sites of the GlmS and GlmU respectively. It is therefore expected that the models and the data provided herein will facilitate translational research to develop new drugs to treat TB. (C) 2015 Published by Elsevier Ltd.
引用
收藏
页码:95 / 111
页数:17
相关论文
共 50 条
  • [31] Enzymes in riboflavin biosynthesis: Potential antibiotic drug targets
    Jaroensuk, Juthamas
    Chuaboon, Litavadee
    Kesornpun, Chatchai
    Chaiyen, Pimchai
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2023, 748
  • [32] Mycobacterium tuberculosis-secreted phosphatases: from pathogenesis to targets for TB drug development
    Wong, Dennis
    Chao, Joseph D.
    Av-Gay, Yossef
    TRENDS IN MICROBIOLOGY, 2013, 21 (02) : 100 - 109
  • [33] Development of drug resistance in Mycobacterium tuberculosis
    Bergval, Indra L.
    Anthony, Richard M.
    Schuitema, Anja R.
    Oskam, Linda
    Klatser, Paul R.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2006, 75 (05): : 118 - 118
  • [34] Enzymes as Targets for Drug Development II
    Kim, Sung-Kun
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
  • [35] Development of a scintillation proximity assay for the Mycobacterium tuberculosis KasA and KasB enzymes involved in mycolic acid biosynthesis
    Schaeffer, ML
    Carson, JD
    Kallender, H
    Lonsdale, JT
    TUBERCULOSIS, 2004, 84 (06) : 353 - 360
  • [36] The Mycobacterium tuberculosis FAS-II condensing enzymes:: their role in mycolic acid biosynthesis, acid-fastness, pathogenesis and in future drug development
    Bhatt, Apoorva
    Molle, Virginie
    Besra, Gurdyal S.
    Jacobs, William R., Jr.
    Kremer, Laurent
    MOLECULAR MICROBIOLOGY, 2007, 64 (06) : 1442 - 1454
  • [37] Biosynthesis of Galactan in Mycobacterium tuberculosis as a Viable TB Drug Target?
    Konyarikova, Zuzana
    Savkova, Karin
    Kozmon, Stanislav
    Mikusova, Katarina
    ANTIBIOTICS-BASEL, 2020, 9 (01):
  • [38] Increasing the structural coverage of tuberculosis drug targets
    Baugh, Loren
    Phan, Isabelle
    Begley, Darren W.
    Clifton, Matthew C.
    Armour, Brianna
    Dranow, David M.
    Taylor, Brandy M.
    Muruthi, Marvin M.
    Abendroth, Jan
    Fairman, James W.
    Fox, David, III
    Dieterich, Shellie H.
    Staker, Bart L.
    Gardberg, Anna S.
    Choi, Ryan
    Hewitt, Stephen N.
    Napuli, Alberto J.
    Myers, Janette
    Barrett, Lynn K.
    Zhang, Yang
    Ferrell, Micah
    Mundt, Elizabeth
    Thompkins, Katie
    Ngoc Tran
    Lyons-Abbott, Sally
    Abramov, Ariel
    Sekar, Aarthi
    Serbzhinskiy, Dmitri
    Lorimer, Don
    Buchko, Garry W.
    Stacy, Robin
    Stewart, Lance J.
    Edwards, Thomas E.
    Van Voorhis, Wesley C.
    Myler, Peter J.
    TUBERCULOSIS, 2015, 95 (02) : 142 - 148
  • [39] Cell wall: A versatile fountain of drug targets in Mycobacterium tuberculosis
    Bhat, Zubair Shanib
    Rather, Muzafar Ahmad
    Maqbool, Mubashir
    UL Lah, Hafiz
    Yousuf, Syed Khalid
    Ahmad, Zahoor
    BIOMEDICINE & PHARMACOTHERAPY, 2017, 95 : 1520 - 1534
  • [40] A Review on Benzimidazole Scaffolds as Inhibitors of Mycobacterium tuberculosis Mycolyl-arabinogalactan-peptidoglycan Complex Biosynthesis
    Bhaskar, Vaishnav
    Kumar, Sunil
    Nair, Aathira S.
    Rajappan, Krishnendu P.
    Sudevan, Sachithra T.
    Parambi, Della G. T.
    Al-Sehemi, Abdullah G.
    Zachariah, Subin M.
    Pappachen, Leena K.
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2023, 26 (04) : 668 - 681